Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.34 |
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198343 | 0.86 | CYP1A2 (0.37) | CYP1A2TSHRHTR2AKMT2ACA1 | |
| SCHEMBL16933080 | 0.86 | CYP1A2 (0.37) | CYP1A2TSHRHTR2AKMT2ACA1 | |
| SCHEMBL23525180 | 0.83 | CYP1A2 (0.35) | CYP1A2TSHRHTR2AKMT2ACA1 | |
| SCHEMBL23525176 | 0.83 | CYP1A2 (0.33) | CYP1A2TSHRHTR2AKMT2ACA1 | |
| SCHEMBL23525416 | 0.82 | CYP1A2 (0.35) | CYP1A2TSHRHTR2AKMT2ACA1 | |
| SCHEMBL23525331 | 0.79 | PPARG (0.34) | CYP1A2TSHRHTR2AKMT2ACA1 | |
| SCHEMBL23525418 | 0.79 | BCHE (0.34) | CYP1A2TSHRPOLBPPARGPPARA | |
| SCHEMBL23525354 | 0.79 | TSHR (0.34) | CYP1A2TSHRHTR2AKMT2ACA1 | |
| SCHEMBL23525396 | 0.79 | CYP1A2 (0.34) | CYP1A2TSHRHTR2AKMT2ACA1 | |
| SCHEMBL23525193 | 0.79 | TSHR (0.34) | CYP1A2TSHRHTR2AKMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188906-A1 | TUBULYSIN ANALOGUES AS ANTICANCER AGENTS AND PAYLOADS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF TREATMENT THEREWITH | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188906-A1 | TUBULYSIN ANALOGUES AS ANTICANCER AGENTS AND PAYLOADS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF TREATMENT THEREWITH | TEK, CD2BP2, SDCBP | CYP1A2 4823/4885TSHR 1917/4885HTR2A 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.